Viral Protein Patents (Class 536/23.72)
  • Publication number: 20150064770
    Abstract: Various aspects and embodiments of the invention are directed to high-throughput phage-engineering methods and recombinant bacteriophages with tunable host ranges for controlling phage specificity.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 5, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Hiroki Ando, Sebastien Lemire
  • Publication number: 20150064214
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: December 4, 2013
    Publication date: March 5, 2015
    Applicant: The USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: 8969536
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: March 3, 2015
    Assignee: Zoetis LLC
    Inventors: Gregory Paul Nitzel, Robert Gerard Ankenbauer, Jay Gregory Calvert, Donna Steuerwald Dunyak, Jacqueline Gayle Marx, Nancee Lois Olen, Douglas Steven Pearce, Mira Ivanova Stoeva, James Richard Thompson
  • Patent number: 8969542
    Abstract: The present invention is directed to HPV polyepitope construct and the use thereof for the prevention and/or treatment of HPV infection.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: March 3, 2015
    Assignees: Genimmune N.V., PHARMEXA Inc.
    Inventors: Marie-Ange Buyse, Denise Baker
  • Publication number: 20150056233
    Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.
    Type: Application
    Filed: August 2, 2014
    Publication date: February 26, 2015
    Inventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
  • Patent number: 8961994
    Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: February 24, 2015
    Assignee: VGX Pharmaceuticals, LLC
    Inventors: Mathura P. Ramanathan, Niranjan Y Sardesai
  • Publication number: 20150050306
    Abstract: The present invention provides polypeptides and compositions thereof for treating or limiting respiratory syncytial virus infection, and computational methods for designing such polypeptides.
    Type: Application
    Filed: April 5, 2013
    Publication date: February 19, 2015
    Inventors: William R. Schief, Bruno E. Correia
  • Publication number: 20150050310
    Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including the immunogens.
    Type: Application
    Filed: January 28, 2013
    Publication date: February 19, 2015
    Inventors: Christian Brander, Beatriz Mothe Pujadas, Anuska Llano
  • Publication number: 20150044255
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Inventors: Jay Gregory CALVERT, Michael G. Sheppard, Siao-Kun W. Welch, Raymond R. R. Rowland, Dal-Young Kim
  • Publication number: 20150044170
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 12, 2015
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • Publication number: 20150044247
    Abstract: Described herein is the generation of optimized H3N2, H2N2 and B influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H3N2, H2N2 and B influenza isolates. Provided herein are optimized H3N2, H2N2 and B influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: February 6, 2013
    Publication date: February 12, 2015
    Inventors: Ted M. Ross, Donald M. Carter, Corey J. Crevar
  • Patent number: 8952144
    Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: February 10, 2015
    Assignee: Uniqure IP B.V.
    Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, Saskia Jacoba Petronella Haast, Dennis Johan Biesmans, Andrew Christian Bakker
  • Publication number: 20150037364
    Abstract: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.
    Type: Application
    Filed: January 15, 2014
    Publication date: February 5, 2015
    Inventors: Charles Chiu, Jean Patterson, Mary Michelle Leland, Kenneth Dee Carey, Dean Ehrdman
  • Patent number: 8946398
    Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: February 3, 2015
    Assignees: Hvidovre Hospital, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
  • Patent number: 8945584
    Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: February 3, 2015
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
  • Publication number: 20150030622
    Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.
    Type: Application
    Filed: July 24, 2014
    Publication date: January 29, 2015
    Inventors: Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
  • Publication number: 20150023995
    Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 22, 2015
    Applicant: TAKEDA VACCINES, INC.
    Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN
  • Publication number: 20150023996
    Abstract: This document relates to polynucleotides encoding antigenic polypeptides to induce an immune response to oncogenic viral polypeptides. Also provided are compositions comprising polynucleotides encoding antigenic polypeptides, and methods of use. In the provided methods, the virus can be a human papilloma virus. In some embodiments, a method for killing a cell expressing a first oncogenic viral polypeptide in a subject is provided. The method includes administering to the subject a composition in an amount sufficient to initiate an immune response against the first oncogenic viral peptide, where the composition comprises a pharmaceutically acceptable carrier and a polynucleotide provided herein and the immune response is effective to cause a cytotoxic effect in the cell. In some embodiments, the polynucleotide includes a second nucleotide sequence encoding a second antigenic polypeptide. The first oncogenic viral polypeptide can be E6 and the second oncogenic viral polypeptide can be E7.
    Type: Application
    Filed: January 23, 2013
    Publication date: January 22, 2015
    Inventors: John H. Lee, Daniel W. Vermeer
  • Patent number: 8936937
    Abstract: Modified expression vectors, including Tobacco Mosaic Virus (TMV) expression vectors, methods for modifying such vectors, and uses of the same are disclosed.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: January 20, 2015
    Assignee: The Ohio State University Research Foundation
    Inventor: John A. Lindbo
  • Publication number: 20150017196
    Abstract: Described herein is the generation of optimized H5N1 and H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H5N1 and H1N1 influenza isolates. Provided herein are optimized H5N1 and H1N1 influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 15, 2015
    Inventors: Ted M. Ross, Corey J. Crevar, Donald M. Carter
  • Patent number: 8932599
    Abstract: The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: January 13, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Paris Est Creteil Val de Marne
    Inventors: Yves Levy, Jean-Marc Balloul, Doris Schmitt, Caterina Riconda Guillet
  • Patent number: 8927701
    Abstract: A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: January 6, 2015
    Assignees: Centre National de la Recherche Scientifique, Les Hospices Civils de Lyon
    Inventors: Bruno Lina, Olivier Terrier, Danielle Françoise Thouvenot
  • Publication number: 20150004190
    Abstract: Novel antibodies and peptides relating to HIV are disclosed, as are vaccine compositions containing such antibodies and peptides. The compounds and compositions of the invention are of use in prevention and treatment of HIV, and in particular for inducing mucosal immunity to HIV.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 1, 2015
    Inventors: Morgane Bomsel, Daniela Tudor
  • Patent number: 8921535
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: December 30, 2014
    Assignee: Zoetis LLC
    Inventors: Gregory Paul Nitzel, Robert Gerard Ankenbauer, Jay Gregory Calvert, Donna Steuerwald Dunyak, Jacqueline Gayle Marx, Nancee Lois Oien, Douglas Steven Pearce, Mira Ivanova Stoeva, James Richard Thompson
  • Patent number: 8921100
    Abstract: The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter. The invention also relates to the uses of said nucleic acid construct.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: December 30, 2014
    Assignee: Technische Universität München
    Inventor: Per Sonne Holm
  • Patent number: 8921655
    Abstract: The present invention relates to the field of functional analysis of Jatropha genes on a genomic scale. More specifically, the present invention relates to a method for high-throughtput functional analysis of Jatropha curcas genes on a genomic scale using virus-induced gene silencing. The method involves use of the tobacco rattle virus (TRV).
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: December 30, 2014
    Assignee: Joil (S) Pte Ltd.
    Inventors: Jian Ye, Nam Hai Chua, Jing Qu
  • Publication number: 20140377775
    Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.
    Type: Application
    Filed: July 29, 2014
    Publication date: December 25, 2014
    Applicant: HYGLOS INVEST GMBH
    Inventors: Stefan MILLER, Roman MEYER, Renate GRASSL, Manfred BIEBL, Holger GRALLERT
  • Patent number: 8916371
    Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 23, 2014
    Assignee: Merial Limited
    Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
  • Patent number: 8916174
    Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: December 23, 2014
    Assignees: National Institute for Agricultural Research, University of Kansas Medical Center
    Inventors: Yahia Chebloune, Euan Narayan
  • Publication number: 20140370051
    Abstract: Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5? and 3? long terminal repeat sequences (LTRs) of the caprine lentivirus: the Caprine Arthritis Encephalitis Virus (CAEV) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described.
    Type: Application
    Filed: September 12, 2012
    Publication date: December 18, 2014
    Inventors: Yahia Chebloune, Delphine Aldebert, Géraldine Arrode-Bruses
  • Patent number: 8911744
    Abstract: The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant CSFV, a method for generating a recombinant CSFV, and use of a recombinant CSFV.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: December 16, 2014
    Assignee: Intervet International B.V.
    Inventors: Jeroen Alexander Kortekaas, Rianka Petronella Maria Vloet
  • Patent number: 8912152
    Abstract: A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 1A representing the Vif wild-type consensus sequence, are replaced with another amino acid, and wherein the nucleotide sequence does not encode the amino acid sequence shown in FIG. 2, representing the Vif sequence of the F12 non-producer variant of HIV-1.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: December 16, 2014
    Assignee: MolMed Spa
    Inventor: Chiara Bovolenta
  • Publication number: 20140363878
    Abstract: The present invention relates to recombinant RNA virus templates derived from and applicable to negative strand naturally non-segmented viruses, including the families Bornaviridae, Filoviridae, and Paramyxoviridae, and methods for generating such recombinant RNA virus templates, wherein the templates are generated from two or more recombinant RNA molecules. The invention relates to the use of segmented recombinant RNA virus templates for naturally non-segmented RNA viruses to express heterologous gene products in appropriate host cell systems and/or to construct recombinant viruses taken from that family and that express, package, and/or present the heterologous gene product. The invention includes the expression products and recombinant and chimeric viruses thus prepared and vaccine and therapeutic formulations comprising the recombinant RNA viruses.
    Type: Application
    Filed: March 11, 2014
    Publication date: December 11, 2014
    Inventors: Adolfo Garcia-Sastre, Peter Palese
  • Publication number: 20140363459
    Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 11, 2014
    Applicant: Ceva Sante Animale
    Inventors: Zoltan Penzes, Anna Kollar, Marianna Ivok
  • Patent number: 8906365
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: December 9, 2014
    Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Publication number: 20140357845
    Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.
    Type: Application
    Filed: November 27, 2012
    Publication date: December 4, 2014
    Inventors: Jan Willem Meijberg, Atonietta Impagliazzo, Ronald Vogels, Robert H.E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
  • Publication number: 20140348865
    Abstract: Disclosed are HIV immunogens. Also disclosed are nucleic acids encoding these immunogens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 27, 2014
    Inventors: Peter Kwong, Jason McLellan, Marie Pancera, Jason Gorman, Mallika Sastry, Kaifan Dai, Tongqing Zhou, John Mascola, Gary Nabel, Masaru Kanekiyo, Yongping Yang, Jiang Zhu, Lai-Xi Wang, William Schief, Chris Carrico, Mohammed Amin
  • Publication number: 20140348863
    Abstract: The present invention relates to immunogenic compositions comprising CMV antigens and methods for preparing compositions that contain CMV antigens. The invention also relates to methods for inducing an immune response to CMV.
    Type: Application
    Filed: October 11, 2012
    Publication date: November 27, 2014
    Inventors: Alessia Bianchi, Luca Bruno, Stefano Calo, Mirko Cortese, Tobias Kessler, Marcello Merola, Yasushi Uematsu
  • Publication number: 20140348798
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: March 7, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
  • Patent number: 8895027
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 25, 2014
    Assignees: Merial Limited, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Hervé Poulet, Thierry Heidmann
  • Publication number: 20140341852
    Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 20, 2014
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Arun Srivastava, George V. Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
  • Publication number: 20140341941
    Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.
    Type: Application
    Filed: December 23, 2013
    Publication date: November 20, 2014
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: DAVID B. WEINER, JIAN YAN
  • Patent number: 8889848
    Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
  • Patent number: 8889849
    Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
  • Patent number: 8889148
    Abstract: Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalian cells. In further aspects of the invention, flavivirus vaccine compositions and methods for vaccination against flavivirus infection are provided.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: November 18, 2014
    Assignee: Research Development Foundation
    Inventors: Dennis T. Brown, Raquel Hernandez
  • Patent number: 8883171
    Abstract: Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: November 11, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles
  • Publication number: 20140328873
    Abstract: The inventors have successfully developed a recombinant vesicular stomatitis virus which expresses the major capsid protein of human norovirus. Infection of mammalian cells with the recombinant vesicular stomatitis virus resulted in production of high level of human norovirus virus-like particles. Importantly, the inventors further demonstrated that recombinant vesicular stomatitis virus expressing the major capsid protein of human norovirus displayed attenuated virulence in mice and elicited a high level of human norovirus-specific humoral, cellular, and mucosal immune responses in mice model. Therefore, norovirus-immunogenic compositions are herein provided, as are materials and methods useful to make and use the compositions.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 6, 2014
    Applicant: OHIO STATE INNOVATION FOUNDATION
    Inventors: Jianrong Li, Yuanmei Ma
  • Publication number: 20140328875
    Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 6, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
  • Publication number: 20140328935
    Abstract: The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 6, 2014
    Inventors: Goaxia Zhang, Qiong Shen, Jianqiang Lei, Jingyu Yuan, Menghua Zhang, Qianli Zhang, Yinghua Xiong, Roger Wei, Ke Wu
  • Patent number: 8877914
    Abstract: The present invention provides compositions comprising a vector including a nucleic acid comprising a nucleotide sequence encoding a peptide having the sequence X1LYQYMDDV, wherein X1 is any hydrophobic amino acid. The compositions are used to induce an immune response against human immunodeficiency virus (HIV).
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: November 4, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Takahiro Okazaki